XORTX Therapeutics Inc.

XRTX
$2.30 (+ $0.04 + 1.77%)
Last updated: 2026-05-30 13:49 UTC
XRTX Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINN/A
Market Price2.3
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend Frequency N/A
P/E RatioN/A
EPS-0.4
Market Cap$3.9M
Book Value0.38
Price to Book1.464
Beta-0.1
52w High1.79
52w Low0.51
Next Earnings DateN/A

XORTX Therapeutics Inc. trades under ticker XRTX on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Also searched as XORTX Therapeutics.

Related researchXRTX stock priceXRTX share priceXORTX Therapeutics stockXORTX Therapeutics share price
About the Company
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Price History